Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...